William H. Rorer, Inc.

Rorer Pharmaceutical Corporation

Rhone-poulenc Rorer Pharmaceuticals Inc.

Rorer Pharmaceutical Corporaton

William L Studt

Henry F Campbell

Donald E Kuhla

Stuart A Dodson

George H Douglas

Bruce F Molino

William C Faith

John Yelnosky

Alfred P Spada

Chong M Won

Harry K Zimmerman

Richard L Riley

Kent W Neuenschwander

Jerome J Zalipsky

Thomas Tucker

Robert A Galemmo, Jr

James Barnes

Ghulam N Mir

George A Condouris

Pamela J Durham

Julius Diamond

Thomas Joseph Tucker

Raymond D Youssefyeh

Matthew R Powers

Billy J Chou

Frederick A Golec

Jacqueline B Krebs

Fang-Ting Chiu

Donald E Kubla

This invention is directed to a method for stereoselectively preparing a syn-dihydroxylated compound comprising reacting a 3-hydroxyket-1-one and a sterically hindered dialkylated borane to form a complex at about -50.degree. C. to about 0.degree. C., and reducing the complex with hydride at about -25.degree. C. to about 50.degree. C.

Stereoselective reduction of 3-hydroxyket-1-ones to

This invention is directed to certain dibenzofurancarboxamides and dibenzofurancarboxamide acids and their use as 5HT.sub.3 antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D.sub.2 receptor binding properties. Further, this invention relates to a process for the synthesis of stereoisomeric compounds having such CNS, anti-emetic and gastric prokinetic activity.

Process for the preparation of optically pure amides

This invention relates to substituted pyridooxazinone and naphtheridone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.

Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic

Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure: ##STR1## where A is ##STR2## R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.9, and R.sub.10 are H, lower alkyl of 1-4 carbon atoms, phenyl, substituted phenyl, phenyl lower alkyl of 1-4 carbon atoms or substituted phenyl lower alkyl of 1-4 carbon atoms; and n is 0 or 1.

Compounds having cardiotonic activity

This invention relates to pyridyl-pyrazolinone compounds of the formula ##STR1## uses of said compounds as cardiotonic agents including methods for increasing cardia contractility and the treatment of congestive heart failure, pharmaceutical compositions including the same and methods for the preparation thereof.

Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in

A method for increasing cardiotonic contractility in humans or other animals using a class of benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds and pharmaceutical compositions including the same.

Method of increasing cardiac contractility using pharmaceutical

This invention relates to substituted pyridooxazinone and naphtheridone pyridazinone and pyrazolone compounds which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.

Pyridazinone and pyrazolone compounds, cardiotonic compositions

Benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds, cardiotonic

Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure ##STR1## wherein: A is ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.8, R.sub.10, R.sub.11, R.sub.12, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23 and R.sub.24 are H, lower alkyl of 1-4 carbon atoms, phenyl, substituted phenyl, phenyl lower alkyl of 1-4 carbon atoms or substituted phenyl lower alkyl of 1-4 carbon atoms;

Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone

A class of bicyclic nitrogen heterocyclic ether and thioether compounds exhibiting pharmacological activity including cytoprotective, H.sub.2 -antagonist, anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions are disclosed.

Bicyclic nitrogen heterocyclic ethers and thioethers, and their

This invention relates to substituted pyridooxazinone pyridazinone and pyrazolone compounds, which are useful as cardiotonic agents for the treatment of congestive heart failure. This invention also relates to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including said compound.

Pyridooxazinone-pyridazinone and pyrazolone compounds, cardiotonic

This invention relates to compounds of the formula ##STR1## where Het is imidazol-1-y or 1,2,4-triozol-1-yl and py is 2-,3- or 4-pyridyl; and the uses of said compounds including methods for increasing cardio contractility and in the treatment of congestive heart failure, pharmaceutical compositions including the same and methods for the preparation thereof.

This invention relates to substituted pyridooxazinone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.

Growing community of inventors

Harleysville, PA, United States of America

William L Studt